doi:10.3969/j.issn.1673-8640.2020.12.023

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 8

[1]	国家卫生健康委办公厅. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-03)[2020-03-10]. .
[2]	GUO L,REN L,YANG S,et al.Profiling early humoral response to diagnose novel coronavirus disease(COVID-19)[J]. Clin Infect Dis,2020,71(15):778-785.
[3]	李萍,李志勇,赵四林,等. 血清2019-nCoV IgM和IgG抗体用于诊断新型冠状病毒肺炎的初探[J]. 中华检验医学杂志,2020,43(4):352-357.
[4]	徐万洲,李娟,何晓云,等. 血清2019新型冠状病毒IgM和IgG抗体联合检测在新型冠状病毒感染中的诊断价值[J]. 中华检验医学杂志,2020,43(3):230-233.
[5]	HSUEH P R,HUANG L M,CHEN P J,et al.Chronological evolution of IgM,IgA,IgG and neutralisation antibodies after infection with SARS-associated coronavirus[J]. Clin Microbiol Infect,2004,10(12):1062-1066.
[6]	石玉玲,李林海,万卓越,等. 传染性非典型肺炎患者血清特异性抗体的变化规律[J]. 中华检验医学杂志,2004,27(12) :14-16
[7]	张瑞,李金明. 2019新型冠状病毒特异抗体检测“假阳性”原因分析及对策[J]. 中华检验医学杂志,2020,43(5):507-510.
[8]	张瑞,李金明. 如何减少新型冠状病毒核酸检测的假阴性[J]. 中华医学杂志,2020,100(11):801-804.

样本编号	C试剂（总抗体）	D试剂		E试剂		F试剂
样本编号	C试剂（总抗体）	IgM抗体	IgG抗体	IgM抗体	IgG抗体	IgM抗体	IgG抗体
1	1:16	1:16	1:16	1:8	1:8	1:16	1:16
2	1:16	1:16	1:16	1:4	1:8	1:16	1:16
3	1:16	1:16	1:16	1:8	1:4	1:16	1:8
4	1:16	1:4	1:16	1:1	1:8	1:16	1:16

样本编号	C试剂（总抗体）	D试剂		E试剂		F试剂
样本编号	C试剂（总抗体）	IgM抗体	IgG抗体	IgM抗体	IgG抗体	IgM抗体	IgG抗体
1	1:16	1:16	1:16	1:8	1:8	1:16	1:16
2	1:16	1:16	1:16	1:4	1:8	1:16	1:16
3	1:16	1:16	1:16	1:8	1:4	1:16	1:8
4	1:16	1:4	1:16	1:1	1:8	1:16	1:16

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 8

Related Articles 15

Recommended Articles

Metrics